SlideShare a Scribd company logo
PHEOCHROMOCYTOMA –
ANAESTHETIC
CONSIDERATIONS
SPEAKER – DR. R HIMA BINDU
MODERATORS – DR. B SRINIVASULU REDDY, DR. SHARWARI AMTE
MALLAREDDY MEDICAL COLLEGE FOR WOMEN
INTRODUCTION
 Catecholamine secreting tumor of chromaffin tissue
 Location: adrenal medulla, extra-adrenal chromaffin cells
ANATOMY
 Paired structures positioned superior and medial to kidneys in retroperitoneal
space
 Supplied by 3 arteries and 1 vein
 Accessory areas for occurrence of pheochromocytoma- Mediastinum, Bladder,
Neck, Sacrococcygeal region, or anal or vaginal areas.
 Organs of Zuckerkandl - paraganglia around the aorta
Cortex • Mesodermal tissue near gonads
Medulla • Chromafin ectodermal cells of neural crest
PHYSIOLOGY
 Adrenal medulla secretes:
 Found in all the chromaffin cells of sympathetic nervous system
EPINEPHRINE NOREPINEPHRINE DOPAMINE
Beta receptor
stimulation
G protein
mediated
activation of
Adenyl cyclase
↑ cAMP
Alpha-1
stimulation
↑Cytoplasmic
Calcium
Smooth
muscle
contraction
Alpha-2
stimulation
Inhibit adenyl
cyclase
↓ cAMP
ADRENAL CORTEX
 Secretes - Mineralocorticoids, Glucocorticoids, and Sex steroids (the androgens
and estrogen)
 Aldosterone, Cortisol
SYMPTOMS
Headache Diaphoresis Palpitations
 Sudden severe headaches, perspiration, weight loss, paroxysmal hypertension, pallor, palpitations,
diabetes-like syndrome with elevated fasting blood sugar, nausea, vomiting, fever, encephalopathy,
anxiety, myocardial infarction, stroke, or acute renal failure.
 A pressor response to particular drugs suggests the presence of this tumor - Histamine, glucagon,
droperidol, tyramine, metoclopramide, cytotoxic drugs, saralasin, tricyclic antidepressants, and
phenothiazines.
PREVALENCE
 Occur in both sexes with peak incidence in the 3rd to 5th decades.
 Traditional “rule of 10” (10% bilateral, 10% extra-adrenal, 10% familial, 10%
malignant)
 20% - Extra adrenal
 25% - Hereditary
 33% - Malignant
 Complication - Cardiomyopathy
ASSOCIATED SYNDROMES
DIAGNOSIS
Urine Tests
• Norepinephrine
• Epinephrine
• Dopamine
• Total metanephrines
• Fractionated
metanephrines
• Vannilylmandelic
acid
Plasma Tests
• Norepinephrine
• Epinephrine
• Dopamine
• Plasma free
metanephrines
• Clonidine
suppression of
norepinephrine
secretion
Imaging
• CT - MIBG
• MRI
A plasma free
normetanephrine level
>400 pg/mL and/or a
metanephrine level
>220 pg/mL confirms
the diagnosis of
pheochromocytoma
PREOPERATIVE OPTIMIZATION
 Major goals : Control hypertension and to facilitate intravascular volume
expansion
 Administration of α-adrenergic blockers –
• Phenoxybenzamine, prazosin, terazosin, doxazosin
 PHENOXYBENZAMINE
 Non-selective, non-competitive, long acting α blocker
 Postoperative refractory hypotension
 Stopped 24-48 hours before surgery
 Dose is 10 mg two or three times a day in adults
 Reflex tachycardia (β1 stimulation)
 Somnolence., Nasal congestion
 PRAZOSIN, TERAZOSIN AND DOXAZOSIN
 Specific α1 adrenergic receptor blockers
 Shorter duration of action
 Lesser side effects
 Prazosin (2-5mg, twice or thrice a day)
 Terazosin (2-5 mg daily)
 Doxazosin (2-8 mg daily)
 α-METHYL-PARA-TYROSINE (α-METYROSINE)
• Decreases the biosynthesis of catecholamines by competitive inhibition.
• Administered a minimum of 2 to 3 days before surgery.
 CALCIUM CHANNEL BLOCKERS
 Inhibit nor-epinephrine induced calcium influx
 Oral Nicardipine 30 mg twice a day is recommended.
 MAGNESIUM SULPHATE
 CAUTION!!! Adequate α blockage may result in tachycardia. This tachycardia is
managed with selective β1 antagonists . β blockers are started only after complete α
blockade.
Assessment of adequate optimization
 ROIZEN CRITERIA for adequate α adrenergic blockade.
Premedication
 Phenoxybenzamine should be stopped 48-72 hours preoperatively
 Selective α blocker – prazosin and doxazosin may be continued till surgery.
 β blockers to be continued if they have been started
 Adequate anxiolysis
 Patients encouraged to consume fluid and salt to facilitate volume expansion.
 Adequate sedation and analgesia – invasive procedues
 Airway – attenuate intubation response
SURGICAL APPROACH
 Commonly done by the laparoscopic approach
 2 approaches - Retroperitoneal and Transabdominal
 Slow insufflation of CO2 , gradual tilting of patient and low intra-abdominal
pressure is recommended
 Risk factors for intraoperative haemodynamic
instabilityarehighpreinductionplasmanorepinephrine levels, large tumor size,
profound postural drop after commencement of α blockade and a preinduction
MAP above 100 mmHg.
INTRAOPERATIVE MANAGEMENT
 Anaesthetic Technique –
• General anaesthesia with intubation and controlled
 Anaesthetic concerns –
• Hypertensive crisis during tumor handling and hypotension after devascularization is a
concern.
• Should prevent catecholamine release by anaesthetic, surgical manoeuvers and drugs.
 Drugs to be avoided - ketamine, suxamethonium, atracurium, pancuronium,
halothane, morphine, pethidine, droperidol and metoclopramide
 Catecholamine release is also provoked by tracheal intubation, raised intra-abdominal
pressure and pain.
 Minimal haemodynamic fluctuations due to tumor handling, as patients are more
prone for severe hypertension and arrhythmias.
 All episodes of hypotension should be managed promptly, especially after tumor
devascularization.
 OT SETUP –
• Ready infusions of nitroglycerine, nitroprusside, nicardipine
• Esmolol for heart rate control
• Vasoconstrictors such as norepinephrine, dopamine and vasopressin
• Colloids for rapid volume expansion
MONITORING
 Electrocardiogram with a V5 lead
 Core temperature
 Pulse oximetry
 Intra-arterial BP monitoring
 Central venous pressure monitoring
 Urinary catheter
 Pulmonary artery catheter or transesophageal echocardiography
ANAESTHETIC MANAGEMENT
 Induction - minimize hemodynamic changes and allow for adequate depth of
anesthesia during tracheal intubation
 Lidocaine 4% solution, 1.5 mg/kg IV
 Inhalational agents –
• Used for maintenance
• Desflurane - may provoke sympathetic stimulation and subsequent catecholamine
release
• Halothane - potential to incite arrhythmias
Drugs to Control Intraoperative
Hypertension
 NICARDIPINE - Infusion of 5–15 mg/hr. ↑ by 2.5 mg/hr every 15 min
 PHENTOLAMINE - 1-mg IV boluses every 5–10 min. Infusion 0.1–2 mg/min
 NITROGLYCERIN - 20–40 μg boluses every 5–10 min to effect. Infusion 5–20
μg/min initial (max dose 400 μg/min)
 NITROPRUSSIDE - Infuse initially with 0.5–1.5 μg/kg/min to maximum of 8
μg/kg/min over 1–3 hr
 PROPRANOLOL - 1-mg boluses to total 10 mg
 ESMOLOL - 5–10-mg boluses, Infuse at 0.25–0.5 μg/kg/min
 LABETALOL - 5–10-mg boluses every 20–30 min to maximum dose 150 mg
Managing hypotension after tumor
devascularization
 BP may decrease very quickly after venous drainage of the tumor is interrupted
 vasodilators being administered should be discontinued
 BP support - vasopressors, such as norepinephrine and vasopressin, and
administering fluids
 Continued vasodilator support may indicate inadequate resection or previously
undiagnosed extra-adrenal tumor
POSTOPERATIVE MANAGEMENT
 Postoperative hypotension can be due to reduced circulating catecholamine levels
post–tumor resection, hypovolemia, or residual effects of phenoxybenzamine.
 Treated with volume administration, norepinephrine, vasopressin
 Patient somnolent – narcotic requirement may decrease.
 Hypoglycemia - result of decreased catecholamine levels (epinephrine secreting
tumour)
 Persistent hypertension after removal of a pheochromocytoma occasionally
signifies - residual pheochromocytoma tumor
THANK YOU
REFERENCES:
1. STOELTING'S ANESTHESIA AND CO-
EXISTING DISEASE – 6TH ED
2. YAO & ARTUSIOS ANESTHESIOLGY,
PROBLEM ORIENTED PATIENT
MANAGEMENT – 9TH ED
3. MILLER’S ANAESTHESIA – 8TH ED

More Related Content

Similar to Pheochromocytoma.pptx

Pheochromocytoma and Anesthesia
Pheochromocytoma and AnesthesiaPheochromocytoma and Anesthesia
Pheochromocytoma and Anesthesia
Tenzin yoezer
 
Anti emetics
Anti emeticsAnti emetics
Anti emetics
Merin Babu
 
Salon a 14 kasim 14.45 16.00 sai̇t karakurt-ing
Salon a 14 kasim 14.45 16.00 sai̇t karakurt-ingSalon a 14 kasim 14.45 16.00 sai̇t karakurt-ing
Salon a 14 kasim 14.45 16.00 sai̇t karakurt-ing
tyfngnc
 
Prolactinoma
ProlactinomaProlactinoma
Prolactinoma
Usman Haqqani
 
Phaeochromocytoma
Phaeochromocytoma  Phaeochromocytoma
Phaeochromocytoma
drjamkar
 
Anti Emetics DR ZIA.pptx
Anti Emetics DR ZIA.pptxAnti Emetics DR ZIA.pptx
Anti Emetics DR ZIA.pptx
DrMuhammadZiaUllahSh
 
Pheochromocytoma
PheochromocytomaPheochromocytoma
Pheochromocytoma
Usama Ragab
 
Sedation and analgesia in picu
Sedation and analgesia in picuSedation and analgesia in picu
Sedation and analgesia in picu
Manoj Prabhakar
 
Post Operative Nausea & Vomiting
Post Operative Nausea & VomitingPost Operative Nausea & Vomiting
Post Operative Nausea & Vomiting
Kiran Rajagopal
 
Anticholinergics and anti emetics
Anticholinergics and anti emeticsAnticholinergics and anti emetics
Anticholinergics and anti emetics
Antara Banerji
 
Antiemetics and prokinetics by dr.roohna
Antiemetics and prokinetics by dr.roohnaAntiemetics and prokinetics by dr.roohna
Antiemetics and prokinetics by dr.roohna
Dr Roohana Hasan
 
Supratentorial tumours
Supratentorial tumoursSupratentorial tumours
Supratentorial tumours
Alvin Cardoz
 
Disorders of adrenal gland
Disorders of adrenal glandDisorders of adrenal gland
Disorders of adrenal gland
ainakadir
 
13361482.ppt
13361482.ppt13361482.ppt
13361482.ppt
SusmithaTalasila
 
Adrenal Gland Tumours and their Management
Adrenal Gland Tumours and their ManagementAdrenal Gland Tumours and their Management
Adrenal Gland Tumours and their Management
Faisal Zia
 
Myasthenia gravis CTVA presentation
Myasthenia gravis CTVA presentationMyasthenia gravis CTVA presentation
Myasthenia gravis CTVA presentation
Kundan Ghimire
 
Cholinergic drugs.pptx
Cholinergic drugs.pptxCholinergic drugs.pptx
Cholinergic drugs.pptx
KrushalPabari
 
Pituitary adenoma
Pituitary adenomaPituitary adenoma
Pituitary adenoma
SumitAgarwal250811
 
Anti cholinergics
Anti cholinergicsAnti cholinergics
Anti cholinergics
Rajib Karmakar
 

Similar to Pheochromocytoma.pptx (20)

Pheochromocytoma and Anesthesia
Pheochromocytoma and AnesthesiaPheochromocytoma and Anesthesia
Pheochromocytoma and Anesthesia
 
Anti emetics
Anti emeticsAnti emetics
Anti emetics
 
Salon a 14 kasim 14.45 16.00 sai̇t karakurt-ing
Salon a 14 kasim 14.45 16.00 sai̇t karakurt-ingSalon a 14 kasim 14.45 16.00 sai̇t karakurt-ing
Salon a 14 kasim 14.45 16.00 sai̇t karakurt-ing
 
Prolactinoma
ProlactinomaProlactinoma
Prolactinoma
 
MTP
MTPMTP
MTP
 
Phaeochromocytoma
Phaeochromocytoma  Phaeochromocytoma
Phaeochromocytoma
 
Anti Emetics DR ZIA.pptx
Anti Emetics DR ZIA.pptxAnti Emetics DR ZIA.pptx
Anti Emetics DR ZIA.pptx
 
Pheochromocytoma
PheochromocytomaPheochromocytoma
Pheochromocytoma
 
Sedation and analgesia in picu
Sedation and analgesia in picuSedation and analgesia in picu
Sedation and analgesia in picu
 
Post Operative Nausea & Vomiting
Post Operative Nausea & VomitingPost Operative Nausea & Vomiting
Post Operative Nausea & Vomiting
 
Anticholinergics and anti emetics
Anticholinergics and anti emeticsAnticholinergics and anti emetics
Anticholinergics and anti emetics
 
Antiemetics and prokinetics by dr.roohna
Antiemetics and prokinetics by dr.roohnaAntiemetics and prokinetics by dr.roohna
Antiemetics and prokinetics by dr.roohna
 
Supratentorial tumours
Supratentorial tumoursSupratentorial tumours
Supratentorial tumours
 
Disorders of adrenal gland
Disorders of adrenal glandDisorders of adrenal gland
Disorders of adrenal gland
 
13361482.ppt
13361482.ppt13361482.ppt
13361482.ppt
 
Adrenal Gland Tumours and their Management
Adrenal Gland Tumours and their ManagementAdrenal Gland Tumours and their Management
Adrenal Gland Tumours and their Management
 
Myasthenia gravis CTVA presentation
Myasthenia gravis CTVA presentationMyasthenia gravis CTVA presentation
Myasthenia gravis CTVA presentation
 
Cholinergic drugs.pptx
Cholinergic drugs.pptxCholinergic drugs.pptx
Cholinergic drugs.pptx
 
Pituitary adenoma
Pituitary adenomaPituitary adenoma
Pituitary adenoma
 
Anti cholinergics
Anti cholinergicsAnti cholinergics
Anti cholinergics
 

More from Tushar Mankar

pulmonary edema pptsssssssssssssssssssss
pulmonary edema pptssssssssssssssssssssspulmonary edema pptsssssssssssssssssssss
pulmonary edema pptsssssssssssssssssssss
Tushar Mankar
 
diabetes mellitus by Tushar 202345.pptx
diabetes mellitus by Tushar 202345.pptxdiabetes mellitus by Tushar 202345.pptx
diabetes mellitus by Tushar 202345.pptx
Tushar Mankar
 
labouranalgesia
labouranalgesialabouranalgesia
labouranalgesia
Tushar Mankar
 
bains circuit copy copy.pptx
bains circuit copy copy.pptxbains circuit copy copy.pptx
bains circuit copy copy.pptx
Tushar Mankar
 
3. Cardiac Arrythmias ppt
3. Cardiac Arrythmias ppt3. Cardiac Arrythmias ppt
3. Cardiac Arrythmias ppt
Tushar Mankar
 
OBSTETRIC PATIENT POSTED FOR NON OBSTETRIC tushar.docx
OBSTETRIC PATIENT POSTED FOR NON OBSTETRIC  tushar.docxOBSTETRIC PATIENT POSTED FOR NON OBSTETRIC  tushar.docx
OBSTETRIC PATIENT POSTED FOR NON OBSTETRIC tushar.docx
Tushar Mankar
 
INFORMED CONSENT
INFORMED CONSENTINFORMED CONSENT
INFORMED CONSENT
Tushar Mankar
 
Spinal epidural
Spinal epiduralSpinal epidural
Spinal epidural
Tushar Mankar
 
OBSTETRIC PATIENT POSTED FOR NON OBSTETRIC.pptx
OBSTETRIC PATIENT POSTED FOR NON OBSTETRIC.pptxOBSTETRIC PATIENT POSTED FOR NON OBSTETRIC.pptx
OBSTETRIC PATIENT POSTED FOR NON OBSTETRIC.pptx
Tushar Mankar
 
Cleft L-P (2).pptx
Cleft L-P (2).pptxCleft L-P (2).pptx
Cleft L-P (2).pptx
Tushar Mankar
 
protocol laptop presentation copy.pptx
protocol laptop presentation copy.pptxprotocol laptop presentation copy.pptx
protocol laptop presentation copy.pptx
Tushar Mankar
 
sympathomimetic
sympathomimeticsympathomimetic
sympathomimetic
Tushar Mankar
 
Spinal anaesthesia tushar.pptx
Spinal anaesthesia tushar.pptxSpinal anaesthesia tushar.pptx
Spinal anaesthesia tushar.pptx
Tushar Mankar
 
Spinal_Anaesthesia copy.pptx
Spinal_Anaesthesia copy.pptxSpinal_Anaesthesia copy.pptx
Spinal_Anaesthesia copy.pptx
Tushar Mankar
 
Perioperative Management of Diabetic Patient.pptx
Perioperative Management of Diabetic Patient.pptxPerioperative Management of Diabetic Patient.pptx
Perioperative Management of Diabetic Patient.pptx
Tushar Mankar
 

More from Tushar Mankar (15)

pulmonary edema pptsssssssssssssssssssss
pulmonary edema pptssssssssssssssssssssspulmonary edema pptsssssssssssssssssssss
pulmonary edema pptsssssssssssssssssssss
 
diabetes mellitus by Tushar 202345.pptx
diabetes mellitus by Tushar 202345.pptxdiabetes mellitus by Tushar 202345.pptx
diabetes mellitus by Tushar 202345.pptx
 
labouranalgesia
labouranalgesialabouranalgesia
labouranalgesia
 
bains circuit copy copy.pptx
bains circuit copy copy.pptxbains circuit copy copy.pptx
bains circuit copy copy.pptx
 
3. Cardiac Arrythmias ppt
3. Cardiac Arrythmias ppt3. Cardiac Arrythmias ppt
3. Cardiac Arrythmias ppt
 
OBSTETRIC PATIENT POSTED FOR NON OBSTETRIC tushar.docx
OBSTETRIC PATIENT POSTED FOR NON OBSTETRIC  tushar.docxOBSTETRIC PATIENT POSTED FOR NON OBSTETRIC  tushar.docx
OBSTETRIC PATIENT POSTED FOR NON OBSTETRIC tushar.docx
 
INFORMED CONSENT
INFORMED CONSENTINFORMED CONSENT
INFORMED CONSENT
 
Spinal epidural
Spinal epiduralSpinal epidural
Spinal epidural
 
OBSTETRIC PATIENT POSTED FOR NON OBSTETRIC.pptx
OBSTETRIC PATIENT POSTED FOR NON OBSTETRIC.pptxOBSTETRIC PATIENT POSTED FOR NON OBSTETRIC.pptx
OBSTETRIC PATIENT POSTED FOR NON OBSTETRIC.pptx
 
Cleft L-P (2).pptx
Cleft L-P (2).pptxCleft L-P (2).pptx
Cleft L-P (2).pptx
 
protocol laptop presentation copy.pptx
protocol laptop presentation copy.pptxprotocol laptop presentation copy.pptx
protocol laptop presentation copy.pptx
 
sympathomimetic
sympathomimeticsympathomimetic
sympathomimetic
 
Spinal anaesthesia tushar.pptx
Spinal anaesthesia tushar.pptxSpinal anaesthesia tushar.pptx
Spinal anaesthesia tushar.pptx
 
Spinal_Anaesthesia copy.pptx
Spinal_Anaesthesia copy.pptxSpinal_Anaesthesia copy.pptx
Spinal_Anaesthesia copy.pptx
 
Perioperative Management of Diabetic Patient.pptx
Perioperative Management of Diabetic Patient.pptxPerioperative Management of Diabetic Patient.pptx
Perioperative Management of Diabetic Patient.pptx
 

Recently uploaded

TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
EugeneSaldivar
 
678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf
CarlosHernanMontoyab2
 
Synthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptxSynthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptx
Pavel ( NSTU)
 
The basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptxThe basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptx
heathfieldcps1
 
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXXPhrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
MIRIAMSALINAS13
 
Acetabularia Information For Class 9 .docx
Acetabularia Information For Class 9  .docxAcetabularia Information For Class 9  .docx
Acetabularia Information For Class 9 .docx
vaibhavrinwa19
 
The approach at University of Liverpool.pptx
The approach at University of Liverpool.pptxThe approach at University of Liverpool.pptx
The approach at University of Liverpool.pptx
Jisc
 
Model Attribute Check Company Auto Property
Model Attribute  Check Company Auto PropertyModel Attribute  Check Company Auto Property
Model Attribute Check Company Auto Property
Celine George
 
How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17
Celine George
 
"Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe..."Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe...
SACHIN R KONDAGURI
 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
siemaillard
 
The Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptxThe Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptx
DhatriParmar
 
Thesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.pptThesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.ppt
EverAndrsGuerraGuerr
 
Additional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdfAdditional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdf
joachimlavalley1
 
Adversarial Attention Modeling for Multi-dimensional Emotion Regression.pdf
Adversarial Attention Modeling for Multi-dimensional Emotion Regression.pdfAdversarial Attention Modeling for Multi-dimensional Emotion Regression.pdf
Adversarial Attention Modeling for Multi-dimensional Emotion Regression.pdf
Po-Chuan Chen
 
Unit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdfUnit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdf
Thiyagu K
 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
DeeptiGupta154
 
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdfUnit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Thiyagu K
 
Home assignment II on Spectroscopy 2024 Answers.pdf
Home assignment II on Spectroscopy 2024 Answers.pdfHome assignment II on Spectroscopy 2024 Answers.pdf
Home assignment II on Spectroscopy 2024 Answers.pdf
Tamralipta Mahavidyalaya
 
Lapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdfLapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdf
Jean Carlos Nunes Paixão
 

Recently uploaded (20)

TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
 
678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf
 
Synthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptxSynthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptx
 
The basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptxThe basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptx
 
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXXPhrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
 
Acetabularia Information For Class 9 .docx
Acetabularia Information For Class 9  .docxAcetabularia Information For Class 9  .docx
Acetabularia Information For Class 9 .docx
 
The approach at University of Liverpool.pptx
The approach at University of Liverpool.pptxThe approach at University of Liverpool.pptx
The approach at University of Liverpool.pptx
 
Model Attribute Check Company Auto Property
Model Attribute  Check Company Auto PropertyModel Attribute  Check Company Auto Property
Model Attribute Check Company Auto Property
 
How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17
 
"Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe..."Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe...
 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
 
The Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptxThe Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptx
 
Thesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.pptThesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.ppt
 
Additional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdfAdditional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdf
 
Adversarial Attention Modeling for Multi-dimensional Emotion Regression.pdf
Adversarial Attention Modeling for Multi-dimensional Emotion Regression.pdfAdversarial Attention Modeling for Multi-dimensional Emotion Regression.pdf
Adversarial Attention Modeling for Multi-dimensional Emotion Regression.pdf
 
Unit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdfUnit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdf
 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
 
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdfUnit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdf
 
Home assignment II on Spectroscopy 2024 Answers.pdf
Home assignment II on Spectroscopy 2024 Answers.pdfHome assignment II on Spectroscopy 2024 Answers.pdf
Home assignment II on Spectroscopy 2024 Answers.pdf
 
Lapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdfLapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdf
 

Pheochromocytoma.pptx

  • 1. PHEOCHROMOCYTOMA – ANAESTHETIC CONSIDERATIONS SPEAKER – DR. R HIMA BINDU MODERATORS – DR. B SRINIVASULU REDDY, DR. SHARWARI AMTE MALLAREDDY MEDICAL COLLEGE FOR WOMEN
  • 2. INTRODUCTION  Catecholamine secreting tumor of chromaffin tissue  Location: adrenal medulla, extra-adrenal chromaffin cells
  • 3. ANATOMY  Paired structures positioned superior and medial to kidneys in retroperitoneal space  Supplied by 3 arteries and 1 vein  Accessory areas for occurrence of pheochromocytoma- Mediastinum, Bladder, Neck, Sacrococcygeal region, or anal or vaginal areas.  Organs of Zuckerkandl - paraganglia around the aorta Cortex • Mesodermal tissue near gonads Medulla • Chromafin ectodermal cells of neural crest
  • 4. PHYSIOLOGY  Adrenal medulla secretes:  Found in all the chromaffin cells of sympathetic nervous system EPINEPHRINE NOREPINEPHRINE DOPAMINE
  • 5.
  • 6. Beta receptor stimulation G protein mediated activation of Adenyl cyclase ↑ cAMP Alpha-1 stimulation ↑Cytoplasmic Calcium Smooth muscle contraction Alpha-2 stimulation Inhibit adenyl cyclase ↓ cAMP
  • 7. ADRENAL CORTEX  Secretes - Mineralocorticoids, Glucocorticoids, and Sex steroids (the androgens and estrogen)  Aldosterone, Cortisol
  • 8. SYMPTOMS Headache Diaphoresis Palpitations  Sudden severe headaches, perspiration, weight loss, paroxysmal hypertension, pallor, palpitations, diabetes-like syndrome with elevated fasting blood sugar, nausea, vomiting, fever, encephalopathy, anxiety, myocardial infarction, stroke, or acute renal failure.  A pressor response to particular drugs suggests the presence of this tumor - Histamine, glucagon, droperidol, tyramine, metoclopramide, cytotoxic drugs, saralasin, tricyclic antidepressants, and phenothiazines.
  • 9. PREVALENCE  Occur in both sexes with peak incidence in the 3rd to 5th decades.  Traditional “rule of 10” (10% bilateral, 10% extra-adrenal, 10% familial, 10% malignant)  20% - Extra adrenal  25% - Hereditary  33% - Malignant  Complication - Cardiomyopathy
  • 11. DIAGNOSIS Urine Tests • Norepinephrine • Epinephrine • Dopamine • Total metanephrines • Fractionated metanephrines • Vannilylmandelic acid Plasma Tests • Norepinephrine • Epinephrine • Dopamine • Plasma free metanephrines • Clonidine suppression of norepinephrine secretion Imaging • CT - MIBG • MRI A plasma free normetanephrine level >400 pg/mL and/or a metanephrine level >220 pg/mL confirms the diagnosis of pheochromocytoma
  • 12. PREOPERATIVE OPTIMIZATION  Major goals : Control hypertension and to facilitate intravascular volume expansion  Administration of α-adrenergic blockers – • Phenoxybenzamine, prazosin, terazosin, doxazosin
  • 13.  PHENOXYBENZAMINE  Non-selective, non-competitive, long acting α blocker  Postoperative refractory hypotension  Stopped 24-48 hours before surgery  Dose is 10 mg two or three times a day in adults  Reflex tachycardia (β1 stimulation)  Somnolence., Nasal congestion
  • 14.  PRAZOSIN, TERAZOSIN AND DOXAZOSIN  Specific α1 adrenergic receptor blockers  Shorter duration of action  Lesser side effects  Prazosin (2-5mg, twice or thrice a day)  Terazosin (2-5 mg daily)  Doxazosin (2-8 mg daily)
  • 15.  α-METHYL-PARA-TYROSINE (α-METYROSINE) • Decreases the biosynthesis of catecholamines by competitive inhibition. • Administered a minimum of 2 to 3 days before surgery.  CALCIUM CHANNEL BLOCKERS  Inhibit nor-epinephrine induced calcium influx  Oral Nicardipine 30 mg twice a day is recommended.  MAGNESIUM SULPHATE  CAUTION!!! Adequate α blockage may result in tachycardia. This tachycardia is managed with selective β1 antagonists . β blockers are started only after complete α blockade.
  • 16. Assessment of adequate optimization  ROIZEN CRITERIA for adequate α adrenergic blockade.
  • 17. Premedication  Phenoxybenzamine should be stopped 48-72 hours preoperatively  Selective α blocker – prazosin and doxazosin may be continued till surgery.  β blockers to be continued if they have been started  Adequate anxiolysis  Patients encouraged to consume fluid and salt to facilitate volume expansion.  Adequate sedation and analgesia – invasive procedues  Airway – attenuate intubation response
  • 18. SURGICAL APPROACH  Commonly done by the laparoscopic approach  2 approaches - Retroperitoneal and Transabdominal  Slow insufflation of CO2 , gradual tilting of patient and low intra-abdominal pressure is recommended  Risk factors for intraoperative haemodynamic instabilityarehighpreinductionplasmanorepinephrine levels, large tumor size, profound postural drop after commencement of α blockade and a preinduction MAP above 100 mmHg.
  • 19. INTRAOPERATIVE MANAGEMENT  Anaesthetic Technique – • General anaesthesia with intubation and controlled  Anaesthetic concerns – • Hypertensive crisis during tumor handling and hypotension after devascularization is a concern. • Should prevent catecholamine release by anaesthetic, surgical manoeuvers and drugs.  Drugs to be avoided - ketamine, suxamethonium, atracurium, pancuronium, halothane, morphine, pethidine, droperidol and metoclopramide  Catecholamine release is also provoked by tracheal intubation, raised intra-abdominal pressure and pain.
  • 20.  Minimal haemodynamic fluctuations due to tumor handling, as patients are more prone for severe hypertension and arrhythmias.  All episodes of hypotension should be managed promptly, especially after tumor devascularization.  OT SETUP – • Ready infusions of nitroglycerine, nitroprusside, nicardipine • Esmolol for heart rate control • Vasoconstrictors such as norepinephrine, dopamine and vasopressin • Colloids for rapid volume expansion
  • 21. MONITORING  Electrocardiogram with a V5 lead  Core temperature  Pulse oximetry  Intra-arterial BP monitoring  Central venous pressure monitoring  Urinary catheter  Pulmonary artery catheter or transesophageal echocardiography
  • 22. ANAESTHETIC MANAGEMENT  Induction - minimize hemodynamic changes and allow for adequate depth of anesthesia during tracheal intubation  Lidocaine 4% solution, 1.5 mg/kg IV  Inhalational agents – • Used for maintenance • Desflurane - may provoke sympathetic stimulation and subsequent catecholamine release • Halothane - potential to incite arrhythmias
  • 23. Drugs to Control Intraoperative Hypertension  NICARDIPINE - Infusion of 5–15 mg/hr. ↑ by 2.5 mg/hr every 15 min  PHENTOLAMINE - 1-mg IV boluses every 5–10 min. Infusion 0.1–2 mg/min  NITROGLYCERIN - 20–40 μg boluses every 5–10 min to effect. Infusion 5–20 μg/min initial (max dose 400 μg/min)  NITROPRUSSIDE - Infuse initially with 0.5–1.5 μg/kg/min to maximum of 8 μg/kg/min over 1–3 hr  PROPRANOLOL - 1-mg boluses to total 10 mg  ESMOLOL - 5–10-mg boluses, Infuse at 0.25–0.5 μg/kg/min  LABETALOL - 5–10-mg boluses every 20–30 min to maximum dose 150 mg
  • 24. Managing hypotension after tumor devascularization  BP may decrease very quickly after venous drainage of the tumor is interrupted  vasodilators being administered should be discontinued  BP support - vasopressors, such as norepinephrine and vasopressin, and administering fluids  Continued vasodilator support may indicate inadequate resection or previously undiagnosed extra-adrenal tumor
  • 25. POSTOPERATIVE MANAGEMENT  Postoperative hypotension can be due to reduced circulating catecholamine levels post–tumor resection, hypovolemia, or residual effects of phenoxybenzamine.  Treated with volume administration, norepinephrine, vasopressin  Patient somnolent – narcotic requirement may decrease.  Hypoglycemia - result of decreased catecholamine levels (epinephrine secreting tumour)  Persistent hypertension after removal of a pheochromocytoma occasionally signifies - residual pheochromocytoma tumor
  • 26. THANK YOU REFERENCES: 1. STOELTING'S ANESTHESIA AND CO- EXISTING DISEASE – 6TH ED 2. YAO & ARTUSIOS ANESTHESIOLGY, PROBLEM ORIENTED PATIENT MANAGEMENT – 9TH ED 3. MILLER’S ANAESTHESIA – 8TH ED

Editor's Notes

  1. metaiodobenzylguanidine (MIBG)
  2. β-Blockers can be a useful adjunct to control BP in the intraoperative phase, particularly if tachycardia accompanies use of systemic vasodilators. They should, however, not be used as the first-line agent for treatment of intraoperative hypertension due to the concern about unopposed α-agonism.